Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION ...
RTÉ Ireland

The science of a hangover

Understanding the chemistry of our food and drink and how they affect our body can help combat the next day hangover ...

Revealed: The UK's most misspelled words – so, have you been writing them correctly?

Experts from WordUnscrambler.pro have revealed the UK's most misspelled words - with a surprising term at the top of the list ...
Taiwan News

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management ...

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics, Inc. reported improved Q3'25 results, with a net loss of $11.9M and $77M in cash. Click here to read why KLRS stock is a Buy.